Dr Dow had used the new generation Abbott ELISA to retest the 69 reactive samples from the multi-centre study. Only 7 were repeatedly reactive, including the 6 which had previously tested positive under supplemental RIBA and PCR testing. The new generation test was likely to be more specific and cause fewer false positive results.